ROYALTY PHARMA PLC- CL A (RPRX) Stock Fundamental Analysis

NASDAQ:RPRX • GB00BMVP7Y09

45.19 USD
+0.39 (+0.87%)
At close: Feb 13, 2026
45.18 USD
-0.01 (-0.02%)
After Hours: 2/13/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

RPRX gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of RPRX get a neutral evaluation. Nothing too spectacular is happening here. RPRX may be a bit undervalued, certainly considering the very reasonable score on growth These ratings would make RPRX suitable for value investing!


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year RPRX was profitable.
  • RPRX had a positive operating cash flow in the past year.
  • Of the past 5 years RPRX 4 years were profitable.
  • RPRX had a positive operating cash flow in 4 of the past 5 years.
RPRX Yearly Net Income VS EBIT VS OCF VS FCFRPRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B

1.2 Ratios

  • RPRX's Return On Assets of 3.95% is amongst the best of the industry. RPRX outperforms 85.34% of its industry peers.
  • Looking at the Return On Equity, with a value of 11.93%, RPRX belongs to the top of the industry, outperforming 86.39% of the companies in the same industry.
  • RPRX's Return On Invested Capital of 6.43% is amongst the best of the industry. RPRX outperforms 84.82% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for RPRX is significantly below the industry average of 12.64%.
  • The last Return On Invested Capital (6.43%) for RPRX is above the 3 year average (5.98%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 3.95%
ROE 11.93%
ROIC 6.43%
ROA(3y)3.97%
ROA(5y)3.7%
ROE(3y)10.17%
ROE(5y)10.3%
ROIC(3y)5.98%
ROIC(5y)6.56%
RPRX Yearly ROA, ROE, ROICRPRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

1.3 Margins

  • RPRX's Profit Margin of 32.55% is amongst the best of the industry. RPRX outperforms 95.29% of its industry peers.
  • In the last couple of years the Profit Margin of RPRX has declined.
  • The Operating Margin of RPRX (65.22%) is better than 100.00% of its industry peers.
  • RPRX's Operating Margin has declined in the last couple of years.
Industry RankSector Rank
OM 65.22%
PM (TTM) 32.55%
GM N/A
OM growth 3Y-2.96%
OM growth 5Y-16.96%
PM growth 3Y11.92%
PM growth 5Y-21.76%
GM growth 3YN/A
GM growth 5YN/A
RPRX Yearly Profit, Operating, Gross MarginsRPRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 50 100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), RPRX is destroying value.
  • There is no outstanding debt for RPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RPRX Yearly Shares OutstandingRPRX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M
RPRX Yearly Total Debt VS Total AssetsRPRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

  • RPRX has an Altman-Z score of 1.84. This is not the best score and indicates that RPRX is in the grey zone with still only limited risk for bankruptcy at the moment.
  • RPRX's Altman-Z score of 1.84 is fine compared to the rest of the industry. RPRX outperforms 61.26% of its industry peers.
  • RPRX has a debt to FCF ratio of 9.47. This is a negative value and a sign of low solvency as RPRX would need 9.47 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 9.47, RPRX belongs to the top of the industry, outperforming 80.10% of the companies in the same industry.
  • A Debt/Equity ratio of 1.34 is on the high side and indicates that RPRX has dependencies on debt financing.
  • The Debt to Equity ratio of RPRX (1.34) is worse than 76.44% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.34
Debt/FCF 9.47
Altman-Z 1.84
ROIC/WACC0.75
WACC8.56%
RPRX Yearly LT Debt VS Equity VS FCFRPRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B

2.3 Liquidity

  • A Current Ratio of 3.48 indicates that RPRX has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 3.48, RPRX is in line with its industry, outperforming 54.97% of the companies in the same industry.
  • A Quick Ratio of 3.48 indicates that RPRX has no problem at all paying its short term obligations.
  • The Quick ratio of RPRX (3.48) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.48
Quick Ratio 3.48
RPRX Yearly Current Assets VS Current LiabilitesRPRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has been growing slightly by 7.80% over the past year.
  • The Earnings Per Share has been growing slightly by 6.39% on average over the past years.
EPS 1Y (TTM)7.8%
EPS 3Y6.39%
EPS 5YN/A
EPS Q2Q%26.96%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%47.14%

3.2 Future

  • Based on estimates for the next years, RPRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.87% on average per year.
  • Based on estimates for the next years, RPRX will show a quite strong growth in Revenue. The Revenue will grow by 8.88% on average per year.
EPS Next Y17.35%
EPS Next 2Y15.67%
EPS Next 3Y16.21%
EPS Next 5Y10.87%
Revenue Next Year2.09%
Revenue Next 2Y4.56%
Revenue Next 3Y9.3%
Revenue Next 5Y8.88%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
RPRX Yearly Revenue VS EstimatesRPRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B 5B
RPRX Yearly EPS VS EstimatesRPRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2 4 6 8

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 10.22 indicates a reasonable valuation of RPRX.
  • Compared to the rest of the industry, the Price/Earnings ratio of RPRX indicates a rather cheap valuation: RPRX is cheaper than 91.62% of the companies listed in the same industry.
  • RPRX's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.68.
  • Based on the Price/Forward Earnings ratio of 8.71, the valuation of RPRX can be described as reasonable.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of RPRX indicates a rather cheap valuation: RPRX is cheaper than 91.10% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of RPRX to the average of the S&P500 Index (28.06), we can say RPRX is valued rather cheaply.
Industry RankSector Rank
PE 10.22
Fwd PE 8.71
RPRX Price Earnings VS Forward Price EarningsRPRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Price/Free Cash Flow ratio, RPRX is valued cheaply inside the industry as 82.72% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 27.61
EV/EBITDA N/A
RPRX Per share dataRPRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

  • RPRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • RPRX has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as RPRX's earnings are expected to grow with 16.21% in the coming years.
PEG (NY)0.59
PEG (5Y)N/A
EPS Next 2Y15.67%
EPS Next 3Y16.21%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. Dividend

5.1 Amount

  • RPRX has a Yearly Dividend Yield of 2.10%.
  • Compared to an average industry Dividend Yield of 1.18, RPRX pays a better dividend. On top of this RPRX pays more dividend than 92.67% of the companies listed in the same industry.
  • RPRX's Dividend Yield is comparable with the S&P500 average which is at 1.84.
Industry RankSector Rank
Dividend Yield 2.1%

5.2 History

  • RPRX has been paying a dividend for over 5 years, so it has already some track record.
  • RPRX has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years4
Div Non Decr Years4
RPRX Yearly Dividends per shareRPRX Yearly Dividends per shareYearly Dividends per share 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6 0.8

5.3 Sustainability

  • 49.36% of the earnings are spent on dividend by RPRX. This is a bit on the high side, but may be sustainable.
DP49.36%
EPS Next 2Y15.67%
EPS Next 3Y16.21%
RPRX Yearly Income VS Free CF VS DividendRPRX Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B
RPRX Dividend Payout.RPRX Dividend Payout, showing the Payout Ratio.RPRX Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

ROYALTY PHARMA PLC- CL A

NASDAQ:RPRX (2/13/2026, 8:00:01 PM)

After market: 45.18 -0.01 (-0.02%)

45.19

+0.39 (+0.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-11
Earnings (Next)05-06
Inst Owners81.5%
Inst Owner Change-86.27%
Ins Owners1.56%
Ins Owner Change8.14%
Market Cap26.09B
Revenue(TTM)N/A
Net Income(TTM)764.96M
Analysts85.71
Price Target48.57 (7.48%)
Short Float %7.09%
Short Ratio6.84
Dividend
Industry RankSector Rank
Dividend Yield 2.1%
Yearly Dividend0.63
Dividend Growth(5Y)N/A
DP49.36%
Div Incr Years4
Div Non Decr Years4
Ex-Date02-20
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.5%
Min EPS beat(2)3.01%
Max EPS beat(2)9.99%
EPS beat(4)3
Avg EPS beat(4)-10%
Min EPS beat(4)-59.9%
Max EPS beat(4)9.99%
EPS beat(8)5
Avg EPS beat(8)-3.29%
EPS beat(12)9
Avg EPS beat(12)0.42%
EPS beat(16)10
Avg EPS beat(16)-0.98%
Revenue beat(2)2
Avg Revenue beat(2)6.07%
Min Revenue beat(2)4.2%
Max Revenue beat(2)7.95%
Revenue beat(4)3
Avg Revenue beat(4)1.88%
Min Revenue beat(4)-14.22%
Max Revenue beat(4)9.61%
Revenue beat(8)3
Avg Revenue beat(8)-6.2%
Revenue beat(12)3
Avg Revenue beat(12)-10.78%
Revenue beat(16)4
Avg Revenue beat(16)-8.96%
PT rev (1m)4.81%
PT rev (3m)9.5%
EPS NQ rev (1m)1.78%
EPS NQ rev (3m)0.53%
EPS NY rev (1m)-3.01%
EPS NY rev (3m)1.8%
Revenue NQ rev (1m)0.95%
Revenue NQ rev (3m)2.79%
Revenue NY rev (1m)1.44%
Revenue NY rev (3m)2.56%
Valuation
Industry RankSector Rank
PE 10.22
Fwd PE 8.71
P/S 11.1
P/FCF 27.61
P/OCF 10.85
P/B 4.07
P/tB 4.75
EV/EBITDA N/A
EPS(TTM)4.42
EY9.78%
EPS(NY)5.19
Fwd EY11.48%
FCF(TTM)1.64
FCFY3.62%
OCF(TTM)4.17
OCFY9.22%
SpS4.07
BVpS11.11
TBVpS9.51
PEG (NY)0.59
PEG (5Y)N/A
Graham Number33.24
Profitability
Industry RankSector Rank
ROA 3.95%
ROE 11.93%
ROCE 8.15%
ROIC 6.43%
ROICexc 7.12%
ROICexgc 7.53%
OM 65.22%
PM (TTM) 32.55%
GM N/A
FCFM 40.2%
ROA(3y)3.97%
ROA(5y)3.7%
ROE(3y)10.17%
ROE(5y)10.3%
ROIC(3y)5.98%
ROIC(5y)6.56%
ROICexc(3y)6.7%
ROICexc(5y)7.58%
ROICexgc(3y)6.7%
ROICexgc(5y)7.59%
ROCE(3y)7.57%
ROCE(5y)8.31%
ROICexgc growth 3Y-4.76%
ROICexgc growth 5Y-18.24%
ROICexc growth 3Y-4.74%
ROICexc growth 5Y-18.16%
OM growth 3Y-2.96%
OM growth 5Y-16.96%
PM growth 3Y11.92%
PM growth 5Y-21.76%
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 1.34
Debt/FCF 9.47
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 62.15%
Interest Coverage -5.67
Cash Conversion N/A
Profit Quality 123.5%
Current Ratio 3.48
Quick Ratio 3.48
Altman-Z 1.84
F-Score5
WACC8.56%
ROIC/WACC0.75
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)92.8%
Cap/Sales(5y)95.39%
Profit Quality(3y)349.23%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.8%
EPS 3Y6.39%
EPS 5YN/A
EPS Q2Q%26.96%
EPS Next Y17.35%
EPS Next 2Y15.67%
EPS Next 3Y16.21%
EPS Next 5Y10.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%47.14%
Revenue Next Year2.09%
Revenue Next 2Y4.56%
Revenue Next 3Y9.3%
Revenue Next 5Y8.88%
EBIT growth 1Y-0.72%
EBIT growth 3Y-3.33%
EBIT growth 5Y-13.2%
EBIT Next Year30.98%
EBIT Next 3Y14.48%
EBIT Next 5Y13.68%
FCF growth 1Y-33.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-13.64%
OCF growth 3Y11.13%
OCF growth 5Y10.68%

ROYALTY PHARMA PLC- CL A / RPRX FAQ

Can you provide the ChartMill fundamental rating for ROYALTY PHARMA PLC- CL A?

ChartMill assigns a fundamental rating of 5 / 10 to RPRX.


What is the valuation status for RPRX stock?

ChartMill assigns a valuation rating of 8 / 10 to ROYALTY PHARMA PLC- CL A (RPRX). This can be considered as Undervalued.


How profitable is ROYALTY PHARMA PLC- CL A (RPRX) stock?

ROYALTY PHARMA PLC- CL A (RPRX) has a profitability rating of 6 / 10.


Can you provide the PE and PB ratios for RPRX stock?

The Price/Earnings (PE) ratio for ROYALTY PHARMA PLC- CL A (RPRX) is 10.22 and the Price/Book (PB) ratio is 4.07.


Can you provide the dividend sustainability for RPRX stock?

The dividend rating of ROYALTY PHARMA PLC- CL A (RPRX) is 4 / 10 and the dividend payout ratio is 49.36%.